Zoledronic acid and clinical fractures and mortality after hip fracture. - Wikidata - awgldk - TriplyDB

Zoledronic acid and clinical fractures and mortality after hip fracture.

Zoledronic acid and clinical fractures and mortality after hip fracture.

http://www.wikidata.org/entity/Q34689802

about

Intravenous zoledronate for postmenopausal osteoporosis European guidance for the diagnosis and management of osteoporosis in postmenopausal women Bisphosphonates: mechanism of action and role in clinical practice Once-yearly zoledronic acid in hip fracture prevention Intravenous zoledronate for osteoporosis: less might be more Bisphosphonates can prevent recurrent hip fracture and reduce the mortality in osteoporotic patient with hip fracture: A meta-analysis Effect of Teriparatide on Healing of Atypical Femoral Fractures: A Systemic Review Medication Related Osteonecrosis of the Jaw: 2015 Position Statement of the Korean Society for Bone and Mineral Research and the Korean Association of Oral and Maxillofacial Surgeons Managing Osteoporosis in Patients on Long-Term Bisphosphonate Treatment: Report of a Task Force of the American Society for Bone and Mineral Research Maximising functional recovery following hip fracture in frail seniors Postoperative management of hip fractures: interventions associated with improved outcomes Treatment of primary osteoporosis in men An overview on the treatment of postmenopausal osteoporosis Atypical Femur Fractures in Patients Treated with Bisphosphonates: Identification, Management, and Prevention 2010 clinical practice guidelines for the diagnosis and management of osteoporosis in Canada: summary Macrophage depletion by free bisphosphonates and zoledronate-loaded red blood cells Controlled delivery of zoledronate improved bone formation locally in vivo A Guide to Improving the Care of Patients with Fragility Fractures, Edition 2 Osteoporosis in Frail Patients: A Consensus Paper of the Belgian Bone Club.Fracture Burden: What Two and a Half Decades of Dubbo Osteoporosis Epidemiology Study Data Reveal About Clinical Outcomes of Osteoporosis.Imminent fracture risk.Mind the (treatment) gap: a global perspective on current and future strategies for prevention of fragility fractures.Risk of subsequent fracture and mortality within 5 years after a non-vertebral fracture Fracture prevention in patients with cognitive impairment presenting with a hip fracture: secondary analysis of data from the HORIZON Recurrent Fracture Trial.Health-related quality of life after vertebral or hip fracture: a seven-year follow-up study.Life Expectancy in Patients Treated for Osteoporosis: Observational Cohort Study Using National Danish Prescription Data.Musculoskeletal decline and mortality: prospective data from the Geelong Osteoporosis Study.Spontaneously recovered severe thrombocytopaenia following zoledronic acid infusion for osteoporosis.Closing the osteoporosis care gap: increased osteoporosis awareness among geriatrics and rehabilitation teams.Bisphosphonates and atrial fibrillation: Bayesian meta-analyses of randomized controlled trials and observational studies.Potential Pitfalls in Collecting and Analyzing Longitudinal Data from Chronically Ill Populations.Prevention of hip fractures in long-term care: relevance of community-derived data.UK clinical guideline for the prevention and treatment of osteoporosis Loss of life years after a hip fracture.Improving osteoporosis care in high-risk home health patients through a high-intensity intervention What are the beliefs, attitudes and practices of front-line staff in long-term care (LTC) facilities related to osteoporosis awareness, management and fracture prevention?Bisphosphonates for treatment of osteoporosis: expected benefits, potential harms, and drug holidays.Prevention of bone loss by zoledronic acid in premenopausal women undergoing adjuvant chemotherapy persist up to one year following discontinuing treatment.Osteoporosis screening and treatment among veterans with recent fracture after implementation of an electronic consult service.Patient perceptions of osteoporosis treatment thresholds

P2860

Q24239823-6B9B32C5-902E-4AC5-BD99-0C15CAED3693 Q24612411-DD13E5F3-C8B4-414F-AC05-8CEEA5F979BD Q24644708-A93F1517-59DA-44B5-86E7-F0D98C4A5EAB Q24657667-DC3F1B58-722F-412F-8227-0863745C10B3 Q26738958-B236C65D-C8C9-4B2B-829F-B8E9842946C6 Q26749442-9F38DEE4-98F0-4D57-9C23-5548D656667F Q26771709-FA625664-6DA9-492C-A240-24C729608DD5 Q26771715-670573E1-2F4C-448E-86C5-0AB86B0E8F3F Q26782621-22EAB0B2-D3EE-4F8C-BF4C-D751216DE486 Q26824069-46DE9699-BAE1-4F12-94E7-942C96948F86 Q26830646-85AFACF0-A864-4D00-BE09-7AD9E7CF45DD Q26991748-0C581220-A594-4B55-8F30-FBADE612713A Q27013070-30A2C662-BE89-4B05-B84C-DECF0C9CAEC4 Q28079133-1B8EF181-73CF-4EF9-A3AE-4C73B13C117D Q28295416-F30FB0AC-2B11-41DC-AE3B-4E50A6F9D81D Q28540086-811A51A9-0163-43F0-8B81-F7EAE10FF902 Q28540762-8D71E540-6DB5-48DB-BD38-102CB58BFA09 Q28647551-B05AE1A7-B820-4113-95C1-F8C15F76A975 Q30235173-581E8258-2BFB-4A26-A405-BA6979913414 Q30235444-715D9C73-BDE6-4031-A9E1-295C2CFDACB0 Q30235569-C9828F51-041E-43ED-B3F7-3CE3BCEA7664 Q30236007-08789795-F9DA-433A-9AC1-A5947834FB72 Q30385752-E29D22C9-EEEF-4A56-B4AD-84BA1C976135 Q30652322-B077C291-4A78-4C78-8592-421E10557D06 Q30877337-1B9A3A26-0A1C-4000-8EB7-D184273DEBFC Q30890172-BD164F53-424C-4877-8144-1642832518BA Q31151507-871E7939-86E0-4630-B479-25CA596818A8 Q33429768-B11CF0C8-20A5-4F45-B3CE-473544883FE3 Q33481990-CE8469BD-C476-4562-8578-0B56868F03F4 Q33505798-8A53DF0A-98FC-45FE-9D3A-8E61CE6AD612 Q33535228-3BF1FE5A-AC51-4138-907A-F7D37830F865 Q33546626-7AFC2083-B07A-4658-A141-488EAE9F9A9A Q33581078-DBB5C376-F6A1-407E-8927-E990E62BF260 Q33660935-FF77189D-3867-454F-82E3-5DDA8FF2FEF4 Q33710755-1B3FD401-10D0-44D0-A45E-C9B653DD2B14 Q33712519-FCCCE042-0CA9-443F-A1BD-C22A2F7C2621 Q33715141-B18FC116-F460-442F-9CBE-5659791C3436 Q33736180-6CF6706D-513A-4800-AE7B-27E60DC3ABA8 Q33759707-D68A9D69-9BD2-4E4A-ACB6-5CE5C84EA84E Q33766971-0364640D-D14A-41CD-9AF1-FC51F8E66BA0

P2860

Zoledronic acid and clinical fractures and mortality after hip fracture.

http://www.wikidata.org/entity/Q34689802

description

2007 nî lūn-bûn

@nan

2007 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած

@hyw

2007 թվականի սեպտեմբերին հրատարակված գիտական հոդված

@hy

2007年の論文

@ja

2007年論文

@yue

2007年論文

@zh-hant

2007年論文

@zh-hk

2007年論文

@zh-mo

2007年論文

@zh-tw

2007年论文

@wuu

name

Zoledronic acid and clinical fractures and mortality after hip fracture.

@ast

Zoledronic acid and clinical fractures and mortality after hip fracture.

@en

Zoledronic acid and clinical fractures and mortality after hip fracture.

@nl

type

label

Zoledronic acid and clinical fractures and mortality after hip fracture.

@ast

Zoledronic acid and clinical fractures and mortality after hip fracture.

@en

Zoledronic acid and clinical fractures and mortality after hip fracture.

@nl

prefLabel

Zoledronic acid and clinical fractures and mortality after hip fracture.

@ast

Zoledronic acid and clinical fractures and mortality after hip fracture.

@en

Zoledronic acid and clinical fractures and mortality after hip fracture.

@nl

P1433

Q34689802-D29A3C5F-E799-4692-A810-819FE45FDF87

P1476

Q34689802-13AA1F99-9F19-4840-BBC7-8B7412CA5CC3

P2093

Q34689802-0C7AF8A0-17BD-4801-ADC4-6BB84753B1C6

Q34689802-1982F32A-55CC-472B-BCD2-73034072F4EF

Q34689802-1C56EEFA-4B98-49FA-8641-23D1565B4BBF

Q34689802-34F8D00B-4053-4395-B068-806B2CC9E577

Q34689802-3FAC72F5-D5E1-4F58-816D-6DBF0B8860AC

Q34689802-84FD3F9F-B9ED-4C05-BDF8-186E3CD1BD67

Q34689802-870A7073-9ADD-4A18-A3D8-54BDCDD3F079

Q34689802-8BCE3CF3-B94B-4A82-BDD6-3D6281CAD2F8

Q34689802-965DB022-0264-4010-ADDF-734B35776686

Q34689802-991C561A-DCBA-42D2-8D27-5C54642CFFD9

P2860

Q34689802-036D211C-61E5-4C37-8995-E798597FAB60

Q34689802-1ABFAF6F-4668-4D26-BC61-D16CBB124F36

Q34689802-25E07385-D8AA-4D6C-BFE0-E587B206D17C

Q34689802-26CEE8AD-EC41-441A-B786-C30857FEB27E

Q34689802-2B5A9EB1-E57F-402E-9A52-F41F55F85C25

Q34689802-35F83515-DDD5-4C49-98F6-55E3C3D91D16

Q34689802-39921F61-B11E-4FE5-9F3A-679361431E24

Q34689802-4985EA03-6C92-457B-8D4E-40D5FE0E8E17

Q34689802-4E19F8FC-6EC8-407B-8270-311BBD2B4577

Q34689802-52142AD5-5D07-45B0-854A-B46D93EC26BA

P304

Q34689802-40D0D79A-5260-4BEE-8AAA-B43297F617FD

P31

Q34689802-947075D9-FA74-488C-BD0B-7F3777D22F46

P356

Q34689802-9526F7FF-F00F-4257-8E04-4BA1627B539D

P407

Q34689802-50783154-E81E-47F4-9D00-B018FAF7E944

P433

Q34689802-78A0DF9E-88D3-4D46-A2C1-E3CFC1B6B928

P478

Q34689802-F8E53705-FA76-4A21-B5C4-761445035291

P577

Q34689802-DAB504E2-DBC6-47C6-A9A9-2F0BC3374857

P698

Q34689802-58CAD940-5151-403E-90E8-679D89B402ED

P932

Q34689802-EFCC2EDF-40EC-486F-8AF5-22E91DC72D37

P356

P1433

The New England Journal of Medicine

P1476

Zoledronic acid and clinical fractures and mortality after hip fracture.

@en

P2093

Carl F Pieper

http://www.w3.org/2001/XMLSchema#string

Carlos Mautalen

http://www.w3.org/2001/XMLSchema#string

Catherine Lavecchia

http://www.w3.org/2001/XMLSchema#string

Cathleen S Colón-Emeric

http://www.w3.org/2001/XMLSchema#string

Chris Recknor

http://www.w3.org/2001/XMLSchema#string

Erik Fink Eriksen

http://www.w3.org/2001/XMLSchema#string

HORIZON Recurrent Fracture Trial

http://www.w3.org/2001/XMLSchema#string

Jay S Magaziner

http://www.w3.org/2001/XMLSchema#string

Jie Zhang

http://www.w3.org/2001/XMLSchema#string

John J Orloff

http://www.w3.org/2001/XMLSchema#string

P2860

Vitamin D deficiency

A multiple testing procedure for clinical trials

The contribution of hip fracture to risk of subsequent fractures: data from two longitudinal studies.

Effect of risedronate on the risk of hip fracture in elderly women. Hip Intervention Program Study Group.

Updated data on proximal femur bone mineral levels of US adults.

Mortality and locomotion 6 months after hospitalization for hip fracture: risk factors and risk-adjusted hospital outcomes.

Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis.

Intravenous zoledronic acid in postmenopausal women with low bone mineral density.

Interventions to improve medication compliance in older patients living in the community: a systematic review of the literature.

Randomized trial to improve fracture prevention in nursing home residents

P304

1799-1809

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1056/NEJMOA074941

http://www.w3.org/2001/XMLSchema#string

P407

P433

18

http://www.w3.org/2001/XMLSchema#string

P478

357

http://www.w3.org/2001/XMLSchema#string

P577

2007-09-17T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

17878149

http://www.w3.org/2001/XMLSchema#string

P932

2324066

http://www.w3.org/2001/XMLSchema#string